Pregabalin Capsule
Product Images NDC 71610-882

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 71610-882). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Bottle Label 50 mg (71610 0882 46)

This text provides information on a medication called Pregabalin in capsule form. It mentions the quantity of 56 capsules with an NDC number of 71610-882-46. The text may also indicate a warning or cautionary information related to the medication.*

FDA Label Image

Aphena Pharma Solutions (TN)

FDA Label Image

Equation (Pregabain Gault Equation)

This text contains a formula for estimating creatinine clearance (CLCr) based on the age, weight, and serum creatinine of a patient. The formula is adjusted for female patients by multiplying it by 0.85.*

FDA Label Image

Fig-01 (Pregabalin Figure 01)

This text provides data on the percentage of patients who experienced improvement in pain after receiving different dosage levels of Pregabalin and a placebo. The percentages range from 0 to 100 for the different dosages, showing the varying levels of improvement observed. This information can be used to evaluate the effectiveness of different doses of Pregabalin in managing pain compared to a placebo.*

FDA Label Image

Fig-02 (Pregabalin Figure 02)

This text provides information on the percentage of patients who showed improvement after taking Pregabalin 100 mg three times a day compared to a placebo. The graph shows the percentage improvement in pain from baseline, with increments of 10 from 0 to 100. It indicates that all patients experienced improvement to some extent, with the percentage increasing gradually.*

FDA Label Image

Fig-03 (Pregabalin Figure 03)

This information highlights the percent of patients who improved with different doses of pregabalin and placebo in relation to pain reduction from baseline. The graph shows a general increase in improvement with higher doses of pregabalin, with the highest improvement seen with pregabalin 300 mg two times a day. This data suggests that higher doses of pregabalin may be more effective in reducing pain compared to lower doses or placebo.*

FDA Label Image

Fig-04 (Pregabalin Figure 04)

This text provides data on the percentage of patients improved with different treatment options for pain management. It includes the use of Pregabalin at two different dosages and a placebo, with corresponding percentage improvements in pain from baseline. The chart also features percentage ranges to aid in evaluating the effectiveness of each treatment option.*

FDA Label Image

Fig-05 (Pregabalin Figure 05)

This table provides information on the percent of patients improved based on different dosages of pregabalin and a placebo. The percentages indicate the level of improvement in pain from the baseline, ranging from 10% to 100%. The two doses of pregabalin mentioned are 50 mg three times a day and 100 mg three times a day. This data can be used to compare the effectiveness of different dosages in managing pain.*

FDA Label Image

Fig-06 (Pregabalin Figure 06)

This appears to be a table showing responder rates (%) for different treatment groups in Study E1 and Study E3. The table includes data for various doses of a placebo and different medications. The responder rates range from 9% to 51%, with some percentages labeled as statistically significant compared to the placebo. The doses of the medications seem to vary between 50mg/day, 150mg/day, 300mg/day, and 600mg/day. The data in the table is presented in a structured format but without further context, the exact nature of the study or medications used is not clear.*

FDA Label Image

Fig-07 (Pregabalin Figure 07)

This information likely pertains to a study or analysis involving different doses of a substance and their effects, with statistical significance indicated by p-values. The graph visualizes the data points and their corresponding p-values, with varying doses (mg/day) shown on the X-axis. The results seem to suggest strong statistical significance with p-values less than or equal to 0.0001 for various comparisons. Please note that only significant p-values are displayed.*

FDA Label Image

Fig-09 (Pregabalin Figure 09)

This data represents the percentage of patients who experienced improvement in pain levels across different dosage levels of Pregabalin and Placebo. The chart shows the breakdown of patients who saw improvement, with the highest percentage of patients experiencing improvement at the 600 mg daily dose of Pregabalin. The percentage of patients improved ranges from above 20% to 100%, indicating the effectiveness of different dosage levels in alleviating pain from baseline.*

FDA Label Image

Fig-10 (Pregabalin Figure 10)

This text provides information about the estimated percentage of subjects without Low Irritant Reaction (LIR) in relation to different doses of Pregabalin and Placebo over a period of days. The chart shows the estimated distribution of subjects across various percentages and doses.*

FDA Label Image

Fig-11 (Pregabalin Figure 11)

This is a chart showing the percentage of subjects who improved from baseline to week 12 under two treatment groups - Pregabalin and Placebo. The data is presented in a graphical format with different percentage values displayed along the x-axis and the corresponding improvement in percentage along the y-axis. This chart can help in comparing the effectiveness of Pregabalin versus Placebo in improving the subjects' condition over the specified time period.*

FDA Label Image

Fig-12 (Pregabalin Figure 12)

This text provides information on the percentage of subjects who showed improvement from baseline to week 16 when taking Pregabalin compared to placebo. The data shows different improvement thresholds from greater than 10% to over 80% for the subjects studied.*

FDA Label Image

Str (Pregabalin Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.